A first-of-its-kind simulated clinical trial has modelled long-term health outcomes for two key Alzheimer’s drugs to determine optimal treatments.
List view / Grid view
The trial will assess the efficacy of a two week regimen of the FDA-approved antibiotic dalbavancin in treating 100 patients with Staphylococcus aureus bacteremia.
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
Drug that strengthens blood vessels allows antibiotics to infiltrate tuberculosis granulomas in mice...
New Phase III data showed Merck’s investigational insomnia medicine suvorexant improved patients’ ability to fall asleep and stay asleep
13 June 2012 | By Merck
New data from two pivotal Phase III trials...
29 May 2009 | By
1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…